LitAlert ~~ GeneLit.com

    • Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer.
    • Lee J, Kim JM, Lee YH, Chong GO, Lee NY, Lee IH, Park JY, Hong DG.
    • In Vivo. 2022 Jul-Aug;36(4):1903-1910. doi: 10.21873/invivo.12910.
    • A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
    • Lee YJ, Seol A, Lee M, Kim JW, Kim HS, Kim K, Suh DH, Kim S, Kim SW, Lee JY.
    • In Vivo. 2022 Jul-Aug;36(4):1949-1958. doi: 10.21873/invivo.12917.

    Identifier: NCT03509246: Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients. (ClinicalTrials.gov)

    • Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk Reducing Mastectomy and Breast Reconstruction.
    • Gandhi A, Duxbury P, Clancy T, Lalloo F, Wisely JA, Kirwan CC, Foden P, Stocking K, Howell A, Evans DG.
    • Plast Reconstr Surg. 2022 Jun 24. doi: 10.1097/PRS.0000000000009383. Epub ahead of print.
    • Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell C, Salih Z, Woodward ER, Lalloo F, Shaw J, Desai S, Crosbie EJ, Edmondson RJ, Schlecht H, Wallace AJ, Jayson GC, Evans DGR.
    • J Clin Pathol. 2022 Jun 23:jclinpath-2022-208369. doi: 10.1136/jcp-2022-208369. Epub ahead of print.
    • Physical Activity in Young BRCA Carriers and Reduced Risk of Breast Cancer.
    • Bucy AM, Valencia CI, Howe CL, Larkin TJ, Conard KD, Anderlik EW, Valdivi SI, Bea JW.
    • Am J Prev Med. 2022 Jun 20:S0749-3797(22)00246-X. doi: 10.1016/j.amepre.2022.04.022. Epub ahead of print.
    • Review
    • Medicaid Expansions: Probing Medicaid's Filling of the Cancer Genetic Testing and Screening Space.
    • Modell SM, Schlager L, Allen CG, Marcus G.
    • Healthcare (Basel). 2022 Jun 8;10(6):1066. doi: 10.3390/healthcare10061066.
    • RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
    • Xie F, Ding D, Lin C, Cunningham D, Wright M, Javed AA, Azad N, Lee V, Donehower R, De Jesus-Acosta A, Le DT, Pishvaian M, Shin EJ, Lennon AM, Khashab M, Singh V, Klein AP, Roberts NJ, Hacker-Prietz A, McPhaul T, Burkhart RA, Burns WR, Narang A, Zaheer A, Fishman EK, Thompson ED, Anders R, Yu J, He J, Wolfgang CL, Zheng L, Liu D, Wu K, Laheru DA.
    • JCO Precis Oncol. 2022 Jun;6:e2100404. doi: 10.1200/PO.21.00404.